{'52WeekChange': 0.27321076,
 'SandP52WeekChange': None,
 'address1': 'Cheung Kong Center',
 'address2': "48th Floor 2 Queen's Road",
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 26.89,
 'askSize': 1100,
 'averageDailyVolume10Day': 219462,
 'averageVolume': 291230,
 'averageVolume10days': 219462,
 'beta': 0.977906,
 'beta3Year': None,
 'bid': 25.4,
 'bidSize': 900,
 'bookValue': 2.16,
 'category': None,
 'circulatingSupply': None,
 'city': 'Central',
 'companyOfficers': [],
 'country': 'Hong Kong',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 26.29,
 'dayLow': 25.68,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -23.158,
 'enterpriseToRevenue': 15.987,
 'enterpriseValue': 3275599104,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '852 2128 1778',
 'fiftyDayAverage': 25.952858,
 'fiftyTwoWeekHigh': 29.92,
 'fiftyTwoWeekLow': 14.74,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 60476294,
 'forwardEps': -0.78,
 'forwardPE': -33.076923,
 'fromCurrency': None,
 'fullTimeEmployees': 853,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.066,
 'heldPercentInstitutions': 0.3065,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1559174400,
 'lastSplitFactor': '1:1',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/chi-med.com',
 'longBusinessSummary': 'Hutchison China MediTech Limited, a commercial-stage '
                        'biopharmaceutical company, engages in the discovery, '
                        'development, and commercialization of targeted '
                        'therapeutics and immunotherapies for oncology and '
                        "immunological diseases in the People's Republic of "
                        'China. It operates through Innovation Platform and '
                        'Commercial Platform segments. The company provides '
                        'research and development services; and develops, '
                        'manufactures, distributes, and markets prescription '
                        'and over-the-counter pharmaceutical products, and '
                        'consumer health products under the Baiyunshan and '
                        'Shang Yao brands. Its clinical stage drugs include '
                        'Savolitinib, an inhibitor for the treatment of '
                        'non-small cell lung cancer, papillary renal cell '
                        'carcinoma, colorectal cancer, gastric cancer, and '
                        'prostate cancer; and Fruquintinib, an inhibitor for '
                        'the treatment of colorectal cancer and solid tumors. '
                        'The company is also developing Surufatinib, an '
                        'inhibitor for the treatment of pancreatic '
                        'neuroendocrine tumors and solid tumors; HMPL-523, an '
                        "inhibitor for the treatment of indolent non-Hodgkin's "
                        'lymphoma; and HMPL-689 for the treatment of indolent '
                        "non-Hodgkin's lymphoma. In addition, it engages in "
                        'the development of HMPL-453, an inhibitor for the '
                        'potential treatment of solid tumors; HMPL-306, a '
                        'molecule dual-inhibitor of isocitrate dehydrogenase 1 '
                        'and 2 for the treatment of hematological '
                        'malignancies, gliomas, and solid tumors; and '
                        'clinical-stage EGFR inhibitors, such as Epitinib and '
                        'theliatinib. Hutchison China MediTech Limited has a '
                        'clinical collaboration agreement with BeiGene, Ltd. '
                        'to evaluate the safety and efficacy of combining '
                        'surufatinib and fruquintinib with BeiGenes anti-PD-1 '
                        'antibody tislelizumab for the treatment of various '
                        'solid tumor cancers. The company was incorporated in '
                        '2000 and is headquartered in Central, Hong Kong. '
                        'Hutchison China MediTech Limited is a subsidiary of '
                        'Hutchison Healthcare Holdings Limited.',
 'longName': 'Hutchison China MediTech Limited',
 'market': 'us_market',
 'marketCap': 3647062272,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_26652603',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1577750400,
 'navPrice': None,
 'netIncomeToCommon': -106024000,
 'nextFiscalYearEnd': 1640908800,
 'open': 26.18,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.69,
 'phone': '852 2121 8200',
 'previousClose': 26.33,
 'priceHint': 2,
 'priceToBook': 11.944444,
 'priceToSalesTrailing12Months': 17.800098,
 'profitMargins': -0.51747,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 26.29,
 'regularMarketDayLow': 25.68,
 'regularMarketOpen': 26.18,
 'regularMarketPreviousClose': 26.33,
 'regularMarketPrice': 26.18,
 'regularMarketVolume': 313188,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 66495800,
 'sharesPercentSharesOut': 0.0081,
 'sharesShort': 1116477,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1069802,
 'shortName': 'Hutchison China MediTech Limite',
 'shortPercentOfFloat': None,
 'shortRatio': 3.33,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'HCM',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.8,
 'twoHundredDayAverage': 23.41964,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '449b4879-f77b-3306-a602-ec54c57e4c31',
 'volume': 313188,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.chi-med.com',
 'yield': None,
 'ytdReturn': None}